文献速递妇科

铂类化疗时代早期恶性卵巢生殖细胞肿瘤淋巴结清扫术的表现

Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
PubMed 文献 · Gynecol Oncol · 2020-04-28

该研究基于美国国家癌症数据库2004至2015年诊断为明显I期恶性卵巢生殖细胞肿瘤的2774例患者,其中1426例(51.4%)接受了淋巴结清扫术。淋巴结转移率为10.3%,但淋巴结清扫术与总生存期无显著关联(5年OS率96.5% vs 97.6%,P=0.81),多因素分析亦未显示生存获益(HR=1.33,95%CI 0.82-2.14)。

要点

  • 明显早期MOGCT中淋巴结转移率10.3%,但淋巴结清扫未改善总生存。
  • 淋巴结清扫组与未清扫组5年OS率分别为96.5%和97.6%,差异无统计学意义。
  • 多因素分析显示淋巴结清扫与生存无关(HR=1.33,95%CI 0.82-2.14)。

核心结论

  • 在明显早期恶性卵巢生殖细胞肿瘤中,淋巴结转移常见,但淋巴结清扫术与生存获益无关。

研究设计与样本

  • 回顾性队列研究,数据来自美国国家癌症数据库,纳入2004至2015年诊断为明显I期MOGCT的2774例患者。

主要发现

  • 1426例(51.4%)接受了淋巴结清扫术,中位切除淋巴结数为9枚(范围1-81),48.3%的患者至少切除10枚淋巴结。
  • 区域淋巴结转移率为10.3%(147例)。
  • 淋巴结清扫组(n=1287)与未清扫组(n=1210)的总生存期无差异,P=0.81;5年OS率分别为96.5%和97.6%。
  • 控制年龄、保险状态、组织学类型、合并症和化疗后,淋巴结清扫与生存无关(HR=1.33,95%CI 0.82-2.14)。

临床怎么用

  • 对于明显早期MOGCT,淋巴结清扫术未显示生存获益,临床决策时应权衡其风险与收益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the patterns of use and impact of lymphadenectomy (LND) on overall survival (OS) of patients with apparent early stage malignant ovarian germ cell tumors (MOGCTs). METHODS: Patients with apparent stage I MOGCT diagnosed between 2004 and 2015 were drawn from the National Cancer Database. The performance of LND was assessed from the pathology report. OS was evaluated using Kaplan-Meier curves, and compared with the log-rank test. A multivariate Cox analysis was performed to control for confounders. RESULTS: A total of 2774 patients were identified; 1426 (51.4%) underwent LND. The median number of lymph nodes (LN) removed was 9 (range 1-81); 48.3% of patients had at least 10 lymph nodes removed. The rate of regional lymph node metastasis was 10.3% (147 patients). There was no difference in OS, between patients who did (n = 1287) and did not (n = 1210) undergo LND, p = 0.81; 5-yr OS rates were 96.5% and 97.6% respectively. After controlling for patient age, insurance status, histology, presence of medical comorbidities, and receipt of chemotherapy, the performance of LND was not associated with better survival (HR: 1.33, 95% CI: 0.82, 2.14). CONCLUSIONS: While LN metastasis is common in apparent early stage MOGCTs, the performance of LND was not associated with a survival benefit.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nasioudis D, Ko EM, Haggerty AF, et al. Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy. Gynecol Oncol. 2020. PMID: 32359845. doi:10.1016/j.ygyno.2020.04.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。